Compounds which have activity at M1 receptor and their uses in medicine

Details for Australian Patent Application No. 2006296369 (hide)

Owner Glaxo Group Limited

Inventors Shi, Dongchuan; Smith, Paul William; Budzik, Brian; Forbes, Ian Thomson; Cooper, David Gwyn; Jin, Jian; Garzya, Vincenzo; Walker, Graham

Agent Davies Collison Cave

Pub. Number AU-A-2006296369

PCT Pub. Number WO2007/036715

Priority 0602040.8 01.02.06 GB; 0519950.0 30.09.05 GB

Filing date 27 September 2006

Wipo publication date 5 April 2007

International Classifications

A61K 31/4184 (2006.01)

A61P 25/00 (2006.01) Drugs for disorders of the nervous system

C07D 235/26 (2006.01) Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings

C07D 405/12 (2006.01) Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom

Event Publications

17 April 2008 PCT application entered the National Phase

  PCT publication WO2007/036715 Priority application(s): WO2007/036715

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2006296371-4- (4-bromo-2-fluoroanilino) - 6-methoxy-7- (l-methylpiperidin-4 - ylmethoxy) quinazoline momohydrate

2006296367-Chemical process